<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36162820</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>21</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>145</Volume><Issue>12</Issue><PubDate><Year>2022</Year><Month>Dec</Month><Day>19</Day></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>The impact of age on genetic testing decisions in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>4440</StartPage><EndPage>4447</EndPage><MedlinePgn>4440-4447</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/brain/awac279</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a heterogeneous neurodegenerative syndrome. In up to 20% of cases, a family history is observed. Although Mendelian disease gene variants are found in apparently sporadic ALS, genetic testing is usually restricted to those with a family history or younger patients with sporadic disease. With the advent of therapies targeting genetic ALS, it is important that everyone treatable is identified. We therefore sought to determine the probability of a clinically actionable ALS genetic test result by age of onset, globally, but using the UK as an exemplar. Blood-derived DNA was sequenced for ALS genes, and the probability of a clinically actionable genetic test result estimated. For a UK subset, age- and sex-specific population incidence rates were used to determine the number of such results missed by restricting testing by age of onset according to UK's National Genomic Test Directory criteria. There were 6274 people with sporadic ALS, 1551 from the UK. The proportion with a clinically actionable genetic test result ranged between 0.21 [95% confidence interval (CI) 0.18-0.25] in the youngest age group to 0.15 (95% CI 0.13-0.17) in the oldest age group for a full gene panel. For the UK, the equivalent proportions were 0.23 (95% CI 0.13-0.33) in the youngest age group to 0.17 (95% CI 0.13-0.21) in the oldest age group. By limiting testing in those without a family history to people with onset below 40 years, 115 of 117 (98% of all, 95% CI 96%-101%) clinically actionable test results were missed. There is a significant probability of a clinically actionable genetic test result in people with apparently sporadic ALS at all ages. Although some countries limit testing by age, doing so results in a significant number of missed pathogenic test results. Age of onset and family history should not be a barrier to genetic testing in ALS.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2022. Published by Oxford University Press on behalf of the Guarantors of Brain.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mehta</LastName><ForeName>Puja R</ForeName><Initials>PR</Initials><Identifier Source="ORCID">0000-0002-0255-407X</Identifier><AffiliationInfo><Affiliation>UCL Queen Square Motor Neuron Disease Centre, Department of Neuromuscular diseases, UCL Queen Square Institute of Neurology, London, WC1N 3BG, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, SE5 9RX, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iacoangeli</LastName><ForeName>Alfredo</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-5280-5017</Identifier><AffiliationInfo><Affiliation>Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, SE5 9RX, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, SE5 8AF, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute for Health Research Biomedical Research Centre and Dementia Unit at South London and Maudsley NHS Foundation Trust and King's College London, London, SE5 8AF, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Opie-Martin</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, SE5 9RX, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Vugt</LastName><ForeName>Joke J F A</ForeName><Initials>JJFA</Initials><Identifier Source="ORCID">0000-0002-4161-4004</Identifier><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht University, Utrecht, 3584 CG, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al Khleifat</LastName><ForeName>Ahmad</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, SE5 9RX, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bredin</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, SE5 9RX, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ossher</LastName><ForeName>Lynn</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, OX3 9DU, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andersen</LastName><ForeName>Peter M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Department of Clinical Science, Neurosciences, Ume&#xe5; University, Ume&#xe5;, SE-901 87, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hardiman</LastName><ForeName>Orla</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Academic Unit of Neurology, Trinity College Dublin, Trinity Biomedical Sciences Institute, Dublin, D02 R590, Republic of Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mehta</LastName><ForeName>Arpan R</ForeName><Initials>AR</Initials><Identifier Source="ORCID">0000-0002-5715-5025</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for MND Research, University of Edinburgh, Edinburgh, EH16 4SB, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fratta</LastName><ForeName>Pietro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>UCL Queen Square Motor Neuron Disease Centre, Department of Neuromuscular diseases, UCL Queen Square Institute of Neurology, London, WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Talbot</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-5490-1697</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, OX3 9DU, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Project MinE ALS Sequencing Consortium</CollectiveName></Author><Author ValidYN="Y"><LastName>Al-Chalabi</LastName><ForeName>Ammar</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4924-7712</Identifier><AffiliationInfo><Affiliation>Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, SE5 9RX, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute for Health Research Biomedical Research Centre and Dementia Unit at South London and Maudsley NHS Foundation Trust and King's College London, London, SE5 8AF, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, King's College Hospital, London, SE5 9RS, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>223-2808-12</GrantID><Agency>Ume&#xe5; University Insamlingsstiftelsen</Agency><Country/></Grant><Grant><Agency>Maudsley Charity</Agency><Country/></Grant><Grant><Agency>Queen Victoria's Freemason's Foundation</Agency><Country/></Grant><Grant><Agency>Darby Rimmer MND Foundation</Agency><Country/></Grant><Grant><Agency>ALS Association Milton Safenowitz Research Fellowship</Agency><Country/></Grant><Grant><GrantID>R01 NS073873</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>2012-0262</GrantID><Agency>Swedish Brain Foundation</Agency><Country/></Grant><Grant><GrantID>ALCHALABI-TALBOT/APR14/926-794</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>2012.0091</GrantID><Agency>Knut and Alice Wallenberg Foundation</Agency><Country/></Grant><Grant><GrantID>2012-3167</GrantID><Agency>Swedish Research Council</Agency><Country/></Grant><Grant><GrantID>NIHR202421</GrantID><Agency>NIHR Senior Investigator</Agency><Country/></Grant><Grant><Agency>IsrALS</Agency><Country/></Grant><Grant><Agency>Spastic Paraplegia Foundation</Agency><Country/></Grant><Grant><Agency>My Name'5 Doddie Foundation</Agency><Country/></Grant><Grant><GrantID>140935</GrantID><Agency>IWT</Agency><Country/></Grant><Grant><GrantID>AL-CHALABI/APR15/844-791</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><Agency>King's College London</Agency><Country/></Grant><Grant><GrantID>MR/R001162/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Agency>Maudsley NHS Foundation Trust</Agency><Country/></Grant><Grant><GrantID>56103-7002829</GrantID><Agency>V&#xe4;sterbotten County Council</Agency><Country/></Grant><Grant><GrantID>R56 NS073873</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>MND Scotland</Agency><Country/></Grant><Grant><GrantID>W.0R20-08</GrantID><Agency>Princes Beatrix Spierfonds</Agency><Country/></Grant><Grant><GrantID>MR/S006508/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><Agency>Ulla-Carin Lindquist Foundation</Agency><Country/></Grant><Grant><GrantID>ES/L008238/1</GrantID><Agency>Economic and Social Research Council</Agency><Country/></Grant><Grant><GrantID>MR/R024804/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Agency>Muscular Dystrophy Association</Agency><Country/></Grant><Grant><Agency>South London and Maudsley NHS Foundation Trust</Agency><Country/></Grant><Grant><GrantID>MEHTA/JUL17/948-795</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><Agency>NIHR Biomedical Research Centre</Agency><Country/></Grant><Grant><GrantID>ALCHALABI-DOBSON/APR14/829-791</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>TR130505</GrantID><Agency>Guy's and St Thomas' Charity</Agency><Country/></Grant><Grant><Agency>Alan Davidson Foundation</Agency><Country/></Grant><Grant><GrantID>102186/B/13/Z</GrantID><Agency>Wellcome Trust Clinical Training Fellowship</Agency><Country/></Grant><Grant><Agency>Rosetrees Trust</Agency><Country/></Grant><Grant><Agency>KU Leuven Opening the Future Fund</Agency><Country/></Grant><Grant><Agency>National Lottery of Belgium</Agency><Country/></Grant><Grant><GrantID>MR/L501529/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Disease" UI="C531617">Amyotrophic lateral sclerosis 1</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005820" MajorTopicYN="N">Genetic Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">age of onset</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">genetic counselling</Keyword><Keyword MajorTopicYN="N">genetic testing</Keyword><Keyword MajorTopicYN="N">motor neuron disease</Keyword></KeywordList><InvestigatorList><Investigator ValidYN="Y"><LastName>Ba&#x15f;ak</LastName><ForeName>Nazli A</ForeName><Initials>NA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Corcia</LastName><ForeName>Philippe</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Couratier</LastName><ForeName>Philippe</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Carvalho</LastName><ForeName>Mamede</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Drory</LastName><ForeName>Vivian</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Glass</LastName><ForeName>Jonathan D</ForeName><Initials>JD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gotkine</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Landers</LastName><ForeName>John E</ForeName><Initials>JE</Initials></Investigator><Investigator ValidYN="Y"><LastName>McLaughlin</LastName><ForeName>Russell</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pardina</LastName><ForeName>Jesus S Mora</ForeName><Initials>JSM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morrison</LastName><ForeName>Karen E</ForeName><Initials>KE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Povedano</LastName><ForeName>Monica</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shaw</LastName><ForeName>Christopher E</ForeName><Initials>CE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shaw</LastName><ForeName>Pamela J</ForeName><Initials>PJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Silani</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ticozzi</LastName><ForeName>Nicola</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Van Damme</LastName><ForeName>Philip</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>van den Berg</LastName><ForeName>Leonard H</ForeName><Initials>LH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Veldink</LastName><ForeName>Jan H</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vourc'h</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weber</LastName><ForeName>Markus</ForeName><Initials>M</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>26</Day><Hour>20</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36162820</ArticleId><ArticleId IdType="pmc">PMC9762932</ArticleId><ArticleId IdType="doi">10.1093/brain/awac279</ArticleId><ArticleId IdType="pii">6694277</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377:162&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston CA, Stanton BR, Turner MR, et al. . Amyotrophic lateral sclerosis in an urban setting: a population based study of inner city London. J Neurol. 2006;253:1642&#x2013;1643.</Citation><ArticleIdList><ArticleId IdType="pubmed">17219036</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Calvo A, Chio A, et al. . Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study. Lancet Neurol. 2014;13:1108&#x2013;1113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4197338</ArticleId><ArticleId IdType="pubmed">25300936</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T, Cudkowicz M, Shaw PJ, et al. . Phase 1&#x2013;2 trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2020;383:109&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RPA, Jones AR, Sproviero W, et al. . Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials. Neurology. 2017;89:1915&#x2013;1922.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5664299</ArticleId><ArticleId IdType="pubmed">28978660</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan M, Heverin M, Doherty MA, et al. . Determining the incidence of familiality in ALS: a study of temporal trends in Ireland from 1994 to 2016. Neurol Genet. 2018;4:e239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5961194</ArticleId><ArticleId IdType="pubmed">29845113</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Lewis CM. Modelling the effects of penetrance and family size on rates of sporadic and familial disease. Hum Hered. 2011;71:281&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pubmed">21846995</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A. Perspective: don&#x2019;t keep it in the family. Nature. 2017; 550:S112.</Citation><ArticleIdList><ArticleId IdType="pubmed">29045374</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta PR, Jones AR, Opie-Martin S, et al. . Younger age of onset in familial amyotrophic lateral sclerosis is a result of pathogenic gene variants, rather than ascertainment bias. J Neurol Neurosurg Psychiatry. 2019;90:268&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6518463</ArticleId><ArticleId IdType="pubmed">30270202</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim YE, Oh KW, Kwon MJ, et al. . De novo FUS mutations in 2 Korean patients with sporadic amyotrophic lateral sclerosis. Neurobiol Aging. 2015;36:1604.e17&#x2013;1604.e19.</Citation><ArticleIdList><ArticleId IdType="pubmed">25457557</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller K, Oh KW, Nordin A, et al. . De novo mutations in SOD1 are a cause of ALS. J Neurol Neurosurg Psychiatry. 2022;93:201&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8784989</ArticleId><ArticleId IdType="pubmed">34518333</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepheard SR, Parker MD, Cooper-Knock J, et al. . Value of systematic genetic screening of patients with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2021;92:510&#x2013;518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8053339</ArticleId><ArticleId IdType="pubmed">33589474</ArticleId></ArticleIdList></Reference><Reference><Citation>
National Genomic Test Directory . Testing Criteria for Rare and Inherited Disease. Accessed 25 November 2021. https://www.england.nhs.uk/wp-content/uploads/2018/08/Rare-and-inherited-disease-eligibility-criteria-2021-22-v2.pdf</Citation></Reference><Reference><Citation>Salmon K, Kiernan MC, Kim SH, et al. . The importance of offering early genetic testing in everyone with amyotrophic lateral sclerosis. Brain. 2022; 145:1207&#x2013;1210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9129091</ArticleId><ArticleId IdType="pubmed">35020823</ArticleId></ArticleIdList></Reference><Reference><Citation>
Project MinE Data Browser . Accessed 2 June 2022. http://databrowser.projectmine.com/</Citation></Reference><Reference><Citation>
Genomics England . Amyotrophic lateral sclerosis/motor neuron disease (Version 1.49). Accessed 25 November 2021. https://panelapp.genomicsengland.co.uk/panels/263/</Citation></Reference><Reference><Citation>van Rheenen W, van der Spek RAA, Bakker MK, et al. . Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nat Genet. 2021;53:1636&#x2013;1648.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8648564</ArticleId><ArticleId IdType="pubmed">34873335</ArticleId></ArticleIdList></Reference><Reference><Citation>Project MinE ALS Sequencing Consortium . Project MinE: study design and pilot analyses of a large-scale whole-genome sequencing study in amyotrophic lateral sclerosis. Eur J Hum Genet. 2018;26:1537&#x2013;1546.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6138692</ArticleId><ArticleId IdType="pubmed">29955173</ArticleId></ArticleIdList></Reference><Reference><Citation>Raczy C, Petrovski R, Saunders CT, et al. . Isaac: ultra-fast whole-genome secondary analysis on illumina sequencing platforms. Bioinformatics. 2013;29:2041&#x2013;2043.</Citation><ArticleIdList><ArticleId IdType="pubmed">23736529</ArticleId></ArticleIdList></Reference><Reference><Citation>McLaren W, Gil L, Hunt SE, et al. . The ensembl variant effect predictor. Genome Biol. 2016;17:122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4893825</ArticleId><ArticleId IdType="pubmed">27268795</ArticleId></ArticleIdList></Reference><Reference><Citation>Eilbeck K, Lewis SE, Mungall CJ, et al. . The sequence ontology: a tool for the unification of genome annotations. Genome Biol. 2005;6:R44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1175956</ArticleId><ArticleId IdType="pubmed">15892872</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolzhenko E, van Vugt J, Shaw RJ, et al. . Detection of long repeat expansions from PCR-free whole-genome sequence data. Genome Res. 2017;27:1895&#x2013;1903.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5668946</ArticleId><ArticleId IdType="pubmed">28887402</ArticleId></ArticleIdList></Reference><Reference><Citation>Tazelaar GHP, Boeynaems S, De Decker M, et al. . ATXN1 Repeat expansions confer risk for amyotrophic lateral sclerosis and contribute to TDP-43 mislocalization. Brain Commun. 2020;2:fcaa064.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7425293</ArticleId><ArticleId IdType="pubmed">32954321</ArticleId></ArticleIdList></Reference><Reference><Citation>Iacoangeli A, Al Khleifat A, Jones AR, et al. . C9orf72 intermediate expansions of 24&#x2013;30 repeats are associated with ALS. Acta Neuropathol Commun. 2019;7:115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6637621</ArticleId><ArticleId IdType="pubmed">31315673</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. . Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Sproviero W, Shatunov A, Stahl D, et al. . ATXN2 Trinucleotide repeat length correlates with risk of ALS. Neurobiol Aging. 2017;51:178.e1&#x2013;178.e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5302215</ArticleId><ArticleId IdType="pubmed">28017481</ArticleId></ArticleIdList></Reference><Reference><Citation>Landrum MJ, Chitipiralla S, Brown GR, et al. . Clinvar: improvements to accessing data. Nucleic Acids Res. 2020;48:D835&#x2013;D844.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6943040</ArticleId><ArticleId IdType="pubmed">31777943</ArticleId></ArticleIdList></Reference><Reference><Citation>Abel O, Powell JF, Andersen PM, Al-Chalabi A. ALSoD: a user-friendly online bioinformatics tool for amyotrophic lateral sclerosis genetics. Hum Mutat. 2012;33:1345&#x2013;1351.</Citation><ArticleIdList><ArticleId IdType="pubmed">22753137</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards S, Aziz N, Bale S, et al. . Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. Genet Med. 2015;17:405&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4544753</ArticleId><ArticleId IdType="pubmed">25741868</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Wang K. Intervar: clinical interpretation of genetic variants by the 2015 ACMG-AMP guidelines. Am J Hum Genet. 2017;100:267&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5294755</ArticleId><ArticleId IdType="pubmed">28132688</ArticleId></ArticleIdList></Reference><Reference><Citation>Opie-Martin S, Ossher L, Bredin A, et al. . Motor neuron disease register for England, Wales and Northern Ireland-an analysis of incidence in England. Amyotroph Lateral Scler Frontotemporal Degener. 2021;22:86&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">32940088</ArticleId></ArticleIdList></Reference><Reference><Citation>
Office for National Statistics . 2011 Census: Additional detailed and local characteristics tables for England and Wales (part 2). LC1117EW&#x2014;Sex by age. Accessed 25 November 2021. https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/datasets/2011censusadditionaldetailedandlocalcharacteristicstablesforenglandandwalespart2</Citation></Reference><Reference><Citation>
Office for National Statistic . 2011 Census: Population estimates by single year of age and sex for local authorities in the United Kingdom. Accessed 25 November 2021. https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/datasets/2011censuspopulationestimatesbysingleyearofageandsexforlocalauthoritiesintheunitedkingdom</Citation></Reference><Reference><Citation>Fay MP, Feuer EJ. Confidence intervals for directly standardized rates: a method based on the gamma distribution. Stat Med. 1997;16:791&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pubmed">9131766</ArticleId></ArticleIdList></Reference><Reference><Citation>Aragon TJ. epitools: Epidemiology Tools. 2020.</Citation></Reference><Reference><Citation>Shefner JM, Al-Chalabi A, Baker MR, et al. . A proposal for new diagnostic criteria for ALS. Clin Neurophysiol. 2020;131:1975&#x2013;1978.</Citation><ArticleIdList><ArticleId IdType="pubmed">32387049</ArticleId></ArticleIdList></Reference><Reference><Citation>
Clinical Genome Resource . Amyotrophic Lateral Sclerosis Spectrum Disorders Gene Curation Expert Panel. Accessed 25 November 2021. https://clinicalgenome.org/affiliation/40096/</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>